Skip to main content
Premium Trial:

Request an Annual Quote

Isis, Genzyme Submit Antisense Cholesterol Drug for European Approval


Isis Pharmaceuticals and Genzyme said this week that they have submitted their antisense-based cholesterol drug mipomersen for European market approval.

Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.

If approved, the companies said the drug would be marketed as Kynamro. A US regulatory submission is expected to be filed later this year.

Isis originally developed mipomersen, and Genzyme acquired the drug's rights in early 2008.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.